Cargando…
Expression of CD133 and CD44 in glioblastoma stem cells correlates with cell proliferation, phenotype stability and intra-tumor heterogeneity
Glioblastoma (GBM) is a heterogeneous tumor of the brain with a poor prognosis due to recurrence and drug resistance following therapy. Genome-wide profiling has revealed the existence of distinct GBM molecular subtypes that respond differently to aggressive therapies. Despite this, molecular subtyp...
Autores principales: | Brown, Daniel V., Filiz, Gulay, Daniel, Paul M., Hollande, Frédéric, Dworkin, Sebastian, Amiridis, Stephanie, Kountouri, Nicole, Ng, Wayne, Morokoff, Andrew P., Mantamadiotis, Theo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328356/ https://www.ncbi.nlm.nih.gov/pubmed/28241049 http://dx.doi.org/10.1371/journal.pone.0172791 |
Ejemplares similares
-
Coexpression analysis of CD133 and CD44 identifies Proneural and Mesenchymal subtypes of glioblastoma multiforme
por: Brown, Daniel V., et al.
Publicado: (2015) -
Sensitivity of GBM cells to cAMP agonist-mediated apoptosis correlates with CD44 expression and agonist resistance with MAPK signaling
por: Daniel, Paul M, et al.
Publicado: (2016) -
The Potential Role of CD44 and CD133 in Colorectal Stem Cell Cancer
por: Abdou Hassan, Wael, et al.
Publicado: (2022) -
Cancer Stem Cell Markers CD44, CD133 in Primary Gastric Adenocarcinoma
por: Nosrati, Anahita, et al.
Publicado: (2014) -
Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer
por: WANG, CHUNXIA, et al.
Publicado: (2012)